SERENA-6: A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibitor A ctDNA Guided Early Switch Study
Date de révision : 22/04/2026
Homme Femme
A partir de 18 ans
Date de début de recrutement : 02/10/2024
Date de fin de recrutement : 08/10/2024
Critères :
Critères d'inclusion :
- Proven diagnosis of adenocarcinoma of the breast with evidence of locoregionally recurrent or metastatic disease not amenable to resection or radiation therapy with curative intent.
- Documentation of histologically confirmed diagnosis of estrogen receptor positive (ER+) /HER2- breast cancer based on local laboratory results.
- Currently on AI (letrozole or anastrozole) + CDK4/6 inhibitor ± LHRH as the initial endocrine based treatment for advanced disease
- Eastern Cooperative Oncology Group performance status of 0 or 1.
- ESR1m detected by central testing of ctDNA
- Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- Adequate organ and marrow function
Critères d'exclusion :
- Advanced, symptomatic, visceral spread, that are at risk of lifethreatening complications in the short term
- Known active uncontrolled or symptomatic CNS metastases, carcinomatous meningitis, or leptomeningeal disease.
- Any evidence of severe or uncontrolled systemic diseases which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol.
- Patient with known or family history of severe heart disease
- Previous treatment with AZD9833, investigational SERDs or fulvestrant.
- Currently pregnant (confirmed with positive pregnancy test) or breastfeeding.
- Persistent non-haematological toxicities (CTCAE Grade > 2) caused by CDK4/6 inhibitor and/or AI treatment.
Lieux et contacts
Informations pratiques pour participer à cet essai.
Comment postuler ?
Pour participer à cet essai clinique, veuillez contacter la personne responsable de l'étude. Vous trouverez ses coordonnées dans la section "Lieux et contacts", puis "Contacts".